Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Nature Cancer is Scopus-indexed (Q1, CiteScore 38.5), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Nature Research.
Checked against the index lists dated .
ISSN 2662-1347Verify ISSN ↗
Publisher: Nature Research
Cost to publish: About US$12,690 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 10 / 428 | 97th | Q1 |
| Cancer Research | 8 / 233 | 96th | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2020–present, best quartile Q1, CiteScore 38.5.
Nature Cancer is Q1 in Oncology (rank 10 of 428) and Q1 in Cancer Research (rank 8 of 233), by CiteScore 2025.
Nature Cancer is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 38.5, which places it in quartile Q1 at the 97th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 12.443, quartile Q1, with an H-index of 102.
The publisher lists an article processing charge of about US$12,690 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Nature Cancer is published by Nature Research. Its ISSN is 2662-1347.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Nature Cancer has an h-index of 133 and a 2-year mean of 17.31 citations per paper (OpenAlex). Its Scopus CiteScore is 38.5, quartile Q1. On 2-year citations it ranks #8 of 424 Scopus journals in Oncology.
Nature Cancer published 204 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 76 research articles (2026), authors are most often from United States (38.4%), China (22.9%) and Germany (5.2%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 2 retracted papers are recorded (1.6 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.